EP
LUCD icon

Essential Partners’s Lucid Diagnostics LUCD Stock Holding History

Essential Partners’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607 Sell
567
-2,271
-80% -$2.45K ﹤0.01% 2431
2026
Q1 		$3.26K Buy
+2,838
New +$3.61K ﹤0.01% 1781
2025
Q4 		– Sell
-1
Closed -$1 – 2859
2025
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 2668

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Essential Partners's LUCD Position: Q2 2026 in Review

Essential Partners reduced its Lucid Diagnostics (LUCD) stake by 80% in Q2 2026, selling an estimated $2.45K and leaving 567 shares worth $607. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

Essential Partners first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.26K in Q1 2026. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Essential Partners held 567 shares of Lucid Diagnostics worth $607 as of Q2 2026.
  • Essential Partners sold 2,271 Lucid Diagnostics shares in Q2 2026, an estimated $2.45K.
  • Lucid Diagnostics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2431 holding.
  • Essential Partners first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • Essential Partners's Lucid Diagnostics position peaked at $3.26K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.